Minnesota is currently home to 2107 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers
NCT05786924
Recruiting
BDTX-4933-101 is a first-in-human, open-label, Phase 1 dose escalation and an expansion cohort study designed to evaluate the safety and tolerability, maximum tolerated dose (MTD) and the preliminary recommended Phase 2 dose (RP2D), and antitumor activity of BDTX-4933. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC) harboring KRAS non-G12C mutations, BRAF, or CRAF (RAF1) mutations, advanced/meta... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Masonic Cancer Center University of Minnesota, Minneapolis, Minnesota
Conditions: Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, Melanoma, Melanoma (Skin), BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Lung Cancer, Recurrent Melanoma, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
Register for Updates
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
NCT05468489
Recruiting
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Health Partners Cancer Center at Regions Hospital, Saint Paul, Minnesota
Conditions: Extensive Stage Small Cell Lung Cancer
Register for Updates
Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults
NCT05465174
Recruiting
The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
Gender:
ALL
Ages:
Between 1 year and 39 years
Trial Updated:
05/22/2025
Locations: Children's Minnesota, Minneapolis, Minnesota
Conditions: Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
Register for Updates
GammaTile and Stupp in Newly Diagnosed GBM
NCT05342883
Recruiting
In summary, standard of care postoperative chemoradiation for patients with newly diagnosed GBM does not routinely provide durable local control or prolonged overall survival. As discussed above it seems unlikely that patient outcomes will be significantly improved with radiation dose escalation given at the time of the EBRT boost. However, as most failures are local, improving LC could potentially improve the OS of patients. To do this, we propose a shift in the traditional radiation paradigm.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Glioblastoma
Register for Updates
InSpace Accelerated Rehabilitation Study
NCT05329584
Recruiting
This is a prospective, parallel group, open-label, multi- center, randomized study to assess two accelerated rehabilitation programs for use with the InSpace device in the treatment of full thickness Massive, Irreparable Rotator Cuff Tears (MIRCTs) performed during an arthroscopic procedure.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
05/22/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Rotator Cuff Tears
Register for Updates
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
NCT04896697
Recruiting
This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the safety and tolerability of vilastobart (XTX101) as monotherapy and vilastobart (XTX101) and atezolizumab combination therapy in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Mayo Clinic Hospital, Rochester, Minnesota
Conditions: Advanced Solid Tumor
Register for Updates
Neurostimulation for Treatment of Chronic Upper Limb Pain After Brachial Plexus Injury
NCT04733599
Recruiting
The purpose of this study is to see how much pain intensity is affected by high frequency spinal cord stimulation therapy in individuals with serious brachial plexus injury.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Brachial Plexus Injury
Register for Updates
Imaging Core Aim 2, and Udall Project 2 Aim 2
NCT06998303
Recruiting
More than one million people in the United States have Parkinson's disease (PD) and the prevalence is expected to double by 2040. Over 60% of these individuals will develop debilitating postural instability and gait disturbances (PIGD), including freezing of gait (FOG). With disease progression, axial motor symptoms typically become resistant to dopamine replacement therapies (e.g. levodopa) and a primary source of disability and morbidity. While subthalamic (STN) and globus pallidus internus (G... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/21/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Parkinson Disease
Register for Updates
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
NCT05832229
Recruiting
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/21/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
Register for Updates
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
NCT05753306
Recruiting
This phase II clinical trial tests how well robotic cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in treating patients with gastric cancer that has spread to the tissue that lines the wall of the abdominal cavity (peritoneum). Gastric cancer is the third leading cause of cancer related deaths worldwide and peritoneal metastasis are found in 30% of patients at time of diagnosis. Patients with peritoneal metastasis have poor survival rates. Traditional surgery is done with a... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/21/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Peritoneum
Register for Updates
Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers
NCT05205343
Recruiting
To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Gastrostomy, Gastric, GastroEsophageal Cancer
Register for Updates
Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.
NCT05024695
Recruiting
Evaluate the safety and effectiveness of iSTAR Medical's MINIject™ implant for lowering intraocular pressure (IOP) in subjects with primary open-angle glaucoma.
Gender:
ALL
Ages:
46 years and above
Trial Updated:
05/21/2025
Locations: Minnesota Eye Consultants, Bloomington, Minnesota
Conditions: Glaucoma
Register for Updates